# Ongoing and future studies on vasculitis in Canada



1st CanVasc meeting – Toronto – 10 June 2011

## Vasculitis trials and studies

### Active in Canada

- ARCHIVE
- PACNS registry
- VCRC longitudinal study
- GCA and MRI (McMaster Khalidi)
- VCRC AGATA GCA/TA
- EUVAS/VCRC/International PEXIVAS
- VCRC one-time DNA + C. Siminovitch (Toronto)

## VCRC longitudinal study

- Hamilton, Toronto
- GCA, TA, PAN, MPA/GPA, CSS

- Visits every
  - 3 months for 2 years then yearly
  - Every year

## VCRC longitudinal study

	Boston University School of Medicine (VCRC)		Cleveland Clinic Foundation (VCRC)		Johns Hopkins University (VCRC)		Mayo Clinic (VCRC)		Mount Sinai Hospital, Toronto (VCRC)		St. Joseph's Hospital, Toronto (VCRC)		University of Pittsburgh (VCRC)		University of Utah (VCRC)		Total	
	Cumulative	Current Year*	Cumulative	Current Year*	Cumulative	Current Year*	Cumulative	Current Year*	Cumulative	Current Year*		Current Year*	Cumulative	Current Year*	Cumulative	Current Year*	Cumulative	Current Year*
5502	19	0	12	0	18	2	45	4	11	2	72	25	1	1	3	3	181	37
5503	36	2	24	1	14	0	23	3	19	2	5	2	3	3	3	3	127	16
5504	14	2	6	0	8	0	7	1	12	2	17	1	1	1	1	1	66	8
5505	68	13	93	0	76	17	56	13	64	19	41	8	5	5	15	15	418	90
5506	28	2	14	1	25	4	13	2	32	8	10	2	0	0	2	2	124	21

Document Navigation

Search

☐ Branding
☐ Grant

Protocol Management Tools

5502 VCRC Longitudinal Protocol for Giant Cell Arteritis

5503 VCRC Longitudinal Protocol for Takayasu's Arteritis

5504 VCRC Longitudinal Protocol for Polyarteritis Nodosa

5505 VCRC Longitudinal Protocol for Wegener's Granulomatosis and Micro...


5506 VCRC Longitudinal Protocol for Churg-Strauss Syndrome

### **AGATA LVV**

- VCRC 5523 (and 5522 for GPA)
- CTLA4-Ig


- 2 Hamilton
- 1 Toronto

- Total 39
- 33+33 Needed



## McMaster's GCA / MRI study

- Dr. Khalidi
- Dr. Clements-Baker
- Dr. Rebello
- Dr. loannidis



Bley et al. Ann Rheum Dis 2009;68:1369-1370







### **PEXIVAS**

a RCT of plasma exchange and glucocorticoid dosing in ANCA associated vasculitis

On behalf of the PEXIVAS Trial Group




## Eligibility

#### **Inclusion**

- New or Previously diagnosed GPA or MPA
- ANCA + (by ELISA)
- Current "severe" manifestation
  - GN with eGFR <50 ml/min</li>
  - Lung hemorrhage
- Informed Consent or Deferred Consent

#### **Exclusion**

- <18 years old (<15 in peds centres)</li>
- Concomitant anti-GBM or other non-AAV vasculitis
- Pregnant
- Received significant therapy for this presentation already
  - >1 IV dose or 2 weeks CYC
  - >1 dose RTX within 1 month
  - >14 days pred >30 mg/day
- Likely has ESRD already
- PLEX or other trial therapy mandated or contraindicated



## Study follow-up


Common study termination point

- Minimal follow-up = 2 years
- Recruitment over 5 years
  - → Maximal follow-up = 7 years

### **Outcomes**

- Primary
  - Composite of ESRD or death
- Secondary
  - Sustained remission at 12 months
  - Adverse events
  - Health related quality of life
  - ESRD
  - Death





Canada (6 June 2011)

2 from St Joseph's Hospital, Hamilton, Ontario, Canada 2 from University of Alberta, Edmonton, Alberta, Canada

London, ON St Michael's, ON



## VCRC Genetic Repository One-Time DNA Protocol

- VCRC 5510
- Aims
  - Collect clinical data and DNA on patients with GCA, TA, PAN, GPA, MPA, CSS
  - Discover genetic markers that increase the risk of developing vasculitis
  - Discover genetic markers linked with certain symptoms of vasculitis
- 93/1,300 patients so far

## VCRC Genetic Repository One-Time DNA Protocol

- GWAS
- Candidate-gene studies and fine-scale genotyping
- 2 x 10ml vials (purple top tubes)
- Sent to BU Genetics Lab. (code bar)
- Local REB approval

## Patients reported outcome studies / driven surveys

 VCRC Reproductive Health in Men and Women with Vasculitis

## **VCRC** patient registry

http://rarediseasesnetwork.epi.usf.edu/vcrc/index.htm



> 2,000

To: Subject: Jennifer Lloyd; Jennifer Lloyd

[TEST] Automation Email Special Message from the VCRC



Visit us at: www.RareDiseasesNetwork.org/vasculitis

## We have a brand new on-line research study open that might be of interest to you! Please read below for more information.

Dear Jennifer Schauble Lloyd

You are invited to participate in an on-line research study being conducted by the Vasculitis Clinical Research Consortium (VCRC) under the direction of Dr. Megan Clowse, from Duke University Medical Center and VCRC investigators at the University of South Florida.

#### Purpose and Background

The purpose of this study is to learn about reproductive health, including fertility and pregnancies, in people with vasculitis.

#### Who Can Take This Survey?

Both men and women with vasculitis age 18 and older can participate in this study.

#### What This Study Involves

This study consists of an online survey. You will be asked to provide answers to a series of questions related to your reproductive health and vasculitis. The consent form explains the research study and your part in the study. If you decide to participate in this confidential research you will be directed to the survey after you read the consent form and choose that you would like to participate. The survey should take about 20-30 minutes of your time.

If you want to participate in this study, please click here.

#### Stay Informed!

We want to keep you informed with the latest news and information. Keeping your contact information up to date can be done quickly and easily on the Web:

Click Here to Update Your Information

#### About the VCRC

The Vasculitis Clinical Research Consortium (VCRC) is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research in different forms of vasculitis and improving the care of patients with vasculitis.

The Vasculitis Clinical Research
Consortium is part of the National
Institutes of Health's Rare Diseases
Clinical Research Network. The VCRC
continues to grow and is working on
several new research projects
concerning vasculitis. Check back with
the VCRC website regularly for updates:

www.RareDiseasesNetwork.org/vasculitis

## 467 responded after 3 email campaigns

The Riare Diseases Clinical Research Network will make every effort to enroil all the patients we can, but we cannot make any guarantees that we will be able to enroil everyone in a particular study who wants to participate. Participate in research study sloes not affect your ability to receive care at any of our Clinical Centers or from other physicians.

## VCRC Reproductive Health in Men and Women with Vasculitis

### Online questionnaire

- 16 pages
- Electronic ICF

### Aims

- Compare infertility rate
   with or without CYC
- Compare pregnancy complication rate before vs after vasculitis onset

VCRC Reproductive Health Survey

#### Reproductive Health Survey

Thank you for volunteering to take part in this important survey.

There is a great need for patients and doctors to understand

- how having vasculitis and its treatment impact a patient's ability to have children;
- how vasculitis in a pregnant woman affects the course of a pregnancy and the health of the newborn;
- iii) how pregnancy impacts vasculitis; and

American Indian orAlaska Native

Black or African American Native Hawaiian or OtherPacific Islander

iv) other issues surrounding reproductive health for both women and men with vasculitis.

We ask women and men of all ages who have had vasculitis to complete the entire survey. The Vasculitis Clinical Research Consortium is conducting this research to collect data directly from patients to better understand many of these complex issues that are so vitally important to patients with vasculitis.

Please be aware that as you answer some of the questions, your screen may freeze and flicker for a few seconds as new information is displayed. This is normal for this program and is supposed to happen. If you need more time to complete the survey, you can save your answers and come back to the survey at another time. You will need to click submit at the end of the survey for your answers to be submitted.

1.	What is your age?		(years)							
2.	Please select the option that best describes your highest level of education.									
	O Didn't go to school		O Some college or Associate Degree							
	O Grade school (1-4 ye	ars)	O College graduate or Baccalaureate Degree							
	O Grade school (5-8 ye	ars)	O Some post-graduate or professional							
	O Some high school (9-	11 years	O Master's Degree							
	O High school diploma	or GED	O Doctoral Degree (Ph.D., M.D., J.D., etc)							
	O Vocational or training school									
3.	Which selection best describes your current marital status?									
	O Married	0	Divorced							
	O Single	0	Widowed							
	O Separated	0	Not married, but in a committed relationship							

Unknown or not reported

## Patients driven survey / reported outcome studies


 VCRC Reproductive Health in Men and Women with Vasculitis

- VCRC Pregnancy registry
- VCRC patient illness perception
- Edmonton study

## **Trials and studies**

## Projects in Canada

- Patients driven survey
- DCVAS
- CanVasc database/cohort
- Sherbrooke practice survey
- Canadian recommendations for diagnosis, management and follow-up



## **DCVAS**

 Each center willing to participate to contact Rashid Luqmani

dcvas@ndorms.ox.ac.uk

Each center will need local REB approval

 US \$15 per patients with full set of data (US \$10 if paper sheet)

## CanVasc database/cohort

### 2 options

- Paper record form to send to CanVasc
- Locally stored Access® CanVasc database (duplicate → synchronizable)

### Every center/MD can participate

- Local REB approval
- Focus on CSS and Takayasu

### Retrospective and prospective

## Important ongoing trials and studies <u>outside</u> Canada

- VCRC AGATA GPA 5522
- CORTAGE
- CHUSPAN2
- REMAIN
- MYCYC
- MAINRITSAN



## (Possibly) important study projects outside Canada

- Rituximab for maintenance (EUVAS)
- Gusperimus in AAV
- Mepolizumab in CSS

## (Possibly) important study projects outside Canada

- Rituximab for maintenance
- Gusperimus
- Mepolizumab
- Apremilast
- Belimumab
- Anti-IL6 receptor
- Complement inhibitors

## Conclusions

- Enroll patients in cohorts/studies/trials!!
  - Rare diseases
  - New treatments
  - Drug cost coverage
- Don't jump over the gun!